Focus Area Cancer Cell Therapy

The Client

  • Well-financed public Biotech company with a differentiated preclinical cell-based platform capable of generating homogenous off-the-shelf engineered adoptive cell therapies (e.g., CART-, CAR-NK, etc.) that could be positioned across a range of cancer types and settings


  • Platform technology positioned as “something for everyone”, lacking clear strategic or messaging direction
  • Lacking internal consensus around optimal positioning (targets, indications) and product profiles (cell types, enabling edits) informed by differentiating platform features, unmet need and the competitive landscape


  • Developed a  robust approach to prioritize among tumor targets based on scientific, clinical & commercial criteria
  • Tailored user-friendly Excel tools to generate rank-ordered lists of targets and enabling edits to inform TPPs
  • Identified develop best-, last-in-class ACT opportunities capable of addressing early-mover shortcomings

Valued Outcome

  • Provided client with supporting insight, rationale, and resources to inform internal decision-making and build consensus among key stakeholders (investors, partners)
  • Company market cap has since more than doubled, and client has advanced multiple candidates into the clinic
  • Lumanity remained a trusted partner for ongoing projects